Another controversial class of antidiabetics with respect to infection risks is the SGLT-2 inhibitor which has been associated with a higher risk of genitourinary tract infections than other antidiabetics due to its hypoglycemic mechanism: SGLT-2 inhibitors downregulate glucose reabsorption by blocking SGLT-2 protein in renal tubules and promote the urinary excretion of glucose22,23. This evidence concerns the gene SLC5A2 and infection.